Adaptive Randomization of Neratinib in Early Breast Cancer

BACKGROUND: I-SPY2, a standing, multicenter, adaptive phase 2 neoadjuvant trial ongoing in high-risk clinical stage II/III breast cancer, is designed to evaluate multiple, novel experimental agents added to standard chemotherapy for their ability to improve the rate of pathologic complete response (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:N Engl J Med
Hauptverfasser: Park, John W., Liu, Minetta C., Yee, Douglas, Yau, Christina, van 't Veer, Laura J., Symmans, W. Fraser, Paoloni, Melissa, Perlmutter, Jane, Hylton, Nola M., Hogarth, Michael, DeMichele, Angela, Buxton, Meredith B., Chien, A. Jo, Wallace, Anne M., Boughey, Judy C., Haddad, Tufia C., Chui, Stephen Y., Kemmer, Kathleen A., Kaplan, Henry G., Isaacs, Claudine, Nanda, Rita, Tripathy, Debasish, Albain, Kathy S., Edmiston, Kirsten K., Elias, Anthony D., Northfelt, Donald W., Pusztai, Lajos, Moulder, Stacy L., Lang, Julie E., Viscusi, Rebecca K., Euhus, David M., Haley, Barbara B., Khan, Qamar J., Wood, William C., Melisko, Michelle, Schwab, Richard, Lyandres, Julia, Davis, Sarah E., Hirst, Gillian L., Sanil, Ashish, Esserman, Laura J., Berry, Donald A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5259558/
https://ncbi.nlm.nih.gov/pubmed/27406346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513750
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge